SurModics, Inc. 

(Public, NASDAQ:SRDX)   Watch this stock   
Find more results for SRDX
Nov 4, 2009
Q4 2009 Earnings Conference Call - Webcast
Nov 4, 2009
Q4 2009 Earnings Release
Sep 17, 2009
CL King and Associates Best Ideas Conference - Webcast
More events from AOL Finance »    

Key stats and ratios

Q3 (Sep '09) 2009
Net profit margin 14.11% 30.90%
Operating margin 20.69% 47.31%
EBITD margin - 52.18%
Return on average assets 5.92% 19.94%
Return on average equity 6.40% 23.90%
Employees 254 -

Address

9924 West 74th Street
Eden Prairie, MN 55344
United States - Map
+1-952-8292700 (Phone)
+1-952-8296743 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Options - Morningstar
Research Reports - Yahoo Finance
Annual Report (PDF) - AnnualReports.com

SurModics, Inc. discussed on blogs

Ranking 1300+ Small Cap Stocks by Cash Flow Per Share - NASD100 ... - Investor's Resources - NASD100.com - Daily Stock Rankings - 13 hours ago

SurModics, Inc. discussions

  View all discussions »

Description

SurModics, Inc. (SurModics) is a provider of drug delivery and surface modification technologies to the healthcare industry. The services provided by the Company include drug delivery technologies (coatings, micro particles and implants); surface modification coating technologies that impart lubricity, prohealing and biocompatibility capabilities, components for in vitro diagnostic test kits, and specialized surfaces for cell culture and microarrays. As of September 30, 2008, SurModics managed its business, through seven technology- and market-focused business units, which includes Drug Delivery, Ophthalmology, Hydrophilic Technologies, Regenerative Technologies, In Vitro Technologies, Orthopedics and Brokwood Pharmaceuticals. In September 2008, it acquired the CodeLink Activated Slide microarray business. In November 2008, it reorganized into four clinically and market-focused business units: Cardiovascular, Ophthalmology, In Vitro Technologies, and Brookwood Pharmaceuticals.

Officers and directors

Robert C. Buhrmaster
Chairman of the Board
Age: 61
Bio & Compensation - Reuters
Bruce J. Barclay
President, Chief Executive Officer, Director
Age: 52
Bio & Compensation - Reuters
Philip D. Ankeny
Chief Financial Officer, Senior Vice President
Age: 45
Bio & Compensation - Reuters
Brian L. Robey
Vice President - Product Development and Operations
Age: 45
Bio & Compensation - Reuters
Aron B. Anderson Ph.D.
Chief Scientific Officer, Vice President
Age: 45
Bio & Compensation - Reuters
Bryan K. Phillips
Vice President, General Counsel, Secretary
Age: 37
Bio & Compensation - Reuters
Jan M. Webster
Vice President - Human Resources
Age: 49
Bio & Compensation - Reuters
Charles W. Olson
Vice President, General Manager - Cardiovascular
Age: 44
Bio & Compensation - Reuters
Lise W. Duran Ph.D.
Vice President - Research
Age: 53
Bio & Compensation - Reuters
Paul A. Lopez
Vice President; President - Ophthalmology Division
Age: 52
Bio & Compensation - Reuters